Postpartum depression

Postpartum depression (PPD), from Latin post partum (after birth), also known as perinatal depression, is a mood disorder which may be experienced by pregnant or postpartum women.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 20 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Postpartum depression (PPD), from Latin post partum (after birth), also known as perinatal depression, is a mood disorder which may be experienced by pregnant or postpartum women. Symptoms include extreme sadness, low energy, anxiety, crying episodes, irritability, and extreme changes in sleeping or eating patterns. PPD can also negatively affect the newborn child.

Although the exact cause of PPD is unclear, it is believed to be due to a combination of physical, emotional, genetic, and social factors such as hormone imbalances and sleep deprivation. Risk factors include prior episodes of postpartum depression, bipolar disorder, a family history of depression, psychological stress, complications of childbirth, lack of support, or a drug use disorder.

Diagnosis is based on a person's symptoms. While most women experience a brief period of worry or unhappiness after delivery, postpartum depression should be suspected when symptoms are severe and last over two weeks. Among those at risk, providing psychosocial support may be protective in preventing PPD.

This may include community support such as food, household chores, mother care, and companionship. Treatment for PPD may include counseling or medications. Types of counseling that are effective include interpersonal psychotherapy (IPT), cognitive behavioral therapy (CBT), and psychodynamic therapy.…

Postpartum depression (PPD), from Latin post partum (after birth), also known as perinatal depression, is a mood disorder which may be experienced by pregnant or postpartum women. Symptoms include extreme sadness, low energy, anxiety, crying episodes, irritability, and extreme changes in sleeping or eating patterns. PPD can also negatively affect the newborn child.

Although the exact cause of PPD is unclear, it is believed to be due to a combination of physical, emotional, genetic, and social factors such as hormone imbalances and sleep deprivation. Risk factors include prior episodes of postpartum depression, bipolar disorder, a family history of depression, psychological stress, complications of childbirth, lack of support, or a drug use disorder.

Diagnosis is based on a person's symptoms. While most women experience a brief period of worry or unhappiness after delivery, postpartum depression should be suspected when symptoms are severe and last over two weeks. Among those at risk, providing psychosocial support may be protective in preventing PPD.

This may include community support such as food, household chores, mother care, and companionship. Treatment for PPD may include counseling or medications. Types of counseling that are effective include interpersonal psychotherapy (IPT), cognitive behavioral therapy (CBT), and psychodynamic therapy.

Tentative evidence supports the use of selective serotonin reuptake inhibitors (SSRIs). Depression occurs in roughly 10 to 20% of postpartum women. Postpartum depression commonly affects mothers who have experienced stillbirth, mothers who live in urban areas, and adolescent mothers.

Moreover, this mood disorder is estimated to affect 1% to 26% of new fathers. A different kind of postpartum mood disorder is postpartum psychosis, which is more severe and occurs in about 1 to 2 per 1,000 women following childbirth.

Postpartum psychosis is one of the leading causes of the murder of children less than one year of age, which occurs in about 8 per 100,000 births in the United States.

Consequences on maternal and child health

Postpartum depression can interfere with normal maternal-infant bonding and adversely affect acute and long-term child development. Infants of mothers with PPD have higher incidences of excess crying, temperamental symptoms, and sleeping difficulties. Problems with sleeping in infants may exacerbate or be exacerbated by concurrent PPD in mothers.

Maternal outcomes of PPD include withdrawal, disengagement, and hostility. Additional patterns observed in mothers with PPD include lower rates of initiation and maintenance of breastfeeding. Children and infants of PPD-affected mothers experience negative long-term impacts on their cognitive functioning, inhibitory control, and emotional regulation.

In cases of untreated PPD, violent behaviors and psychiatric and medical conditions in adolescence have been observed. Suicide rates of women with PPD are lower than those outside of the perinatal period. Fetal or infant death in the first year postpartum has been associated with a higher risk of suicide attempt and higher inpatient psychiatric admissions.

Adoptive parents

Postpartum depression may also be experienced by non-biological parents. While not much research has been done regarding post-adoption depression, difficulties associated with parenting post-partum are similar between biological and adoptive parents. Women who adopt children undergo significant stress and life changes during the postpartum period, similar to biological mothers.

This may raise their chance of developing depressive symptoms and anxious tendencies. Postpartum depression presents in adoptive mothers via sleep deprivation similar to birth mothers, but adoptive parents may have added risk factors such as a history of infertility.

Issues for LGBTQ people

Additionally, preliminary research has shown that childbearing individuals who are part of the LGBTQ community may be more susceptible to prenatal depression and anxiety than cisgender and heterosexual people. According to two other studies, LGBTQ people were discouraged from accessing postpartum mental health services due to societal stigma adding a social barrier that heteronormative mothers do not have.

Lesbian participants expressed apprehension about receiving a mental health diagnosis because of worries about social stigma and employment opportunities. Concerns were also raised about possible child removal and a parent's diagnosis including mental illness.

From the studies conducted thus far, although limited, it is evident that there is a much larger population that experiences depression associated with childbirth than just biological mothers.

Causes

The cause of PPD is unknown. Hormonal and physical changes, personal and family history of depression, and the stress of caring for a new baby all may contribute to the development of postpartum depression. Evidence suggests that hormonal changes may play a role.

Understanding the neuroendocrinology characteristic of PPD has proven to be particularly challenging given the erratic changes to the brain and biological systems during pregnancy and postpartum. A review of exploratory studies in PPD has observed that women with PPD have more dramatic changes in HPA axis activity, however, the directionality of specific hormone increases or decreases remain mixed.

Hormones that have been studied include estrogen, progesterone, thyroid hormone, testosterone, corticotropin releasing hormone, endorphins, and cortisol. Estrogen and progesterone levels drop back to pre-pregnancy levels within 24 hours of giving birth, and that sudden change may cause it.

Aberrant steroid hormone-dependent regulation of neuronal calcium influx via extracellular matrix proteins and membrane receptors involved in responding to the cell's microenvironment might be important in conferring biological risk. The use of synthetic oxytocin, a birth-inducing drug, has been linked to increased rates of postpartum depression and anxiety.

Allopregnanolone, a derivative of progesterone, has been linked to the pathophysiology of PPD due to its role in modulating GABA receptors. Allopregnanolone levels dramatically decrease following childbirth. A decline in allopregnanolone has been associated with depression like symptoms in mice.

Estradiol, which helps the uterus thicken and grow, is thought to contribute to the development of PPD. This is due to its relationship with serotonin. Estradiol levels increase during pregnancy, then drastically decrease following childbirth.

When estradiol levels drop postpartum, the levels of serotonin decline as well. Serotonin is a neurotransmitter that helps regulate mood. Low serotonin levels cause feelings of depression and anxiety.

Thus, when estradiol levels are low, serotonin can be low, suggesting that estradiol plays a role in the development of PPD. Profound lifestyle changes that are brought about by caring for the infant are also frequently hypothesized to cause PPD. However, little evidence supports this hypothesis.

Mothers who have had several previous children without experiencing PPD can nonetheless experience it with their latest child. Despite the biological and psychosocial changes that may accompany pregnancy and the postpartum period, most women are not diagnosed with PPD. Many mothers are unable to get the rest they need to fully recover from giving birth.

Sleep deprivation can lead to physical discomfort and exhaustion, which can contribute to the symptoms of postpartum depression.

Violence

A meta-analysis reviewing research on the association of violence and postpartum depression showed that violence against women increases the incidence of postpartum depression. About one-third of women throughout the world will experience physical or sexual violence at some point in their lives. Violence against women occurs in conflict, post-conflict, and non-conflict areas.

The research reviewed only looked at violence experienced by women from male perpetrators. Studies from the Middle East suggest that individuals who have experienced family violence are 2.5 times more likely to develop PPD.

Further, violence against women was defined as "any act of gender-based violence that results in, or is likely to result in, physical, sexual, or psychological harm or suffering to women". Psychological and cultural factors associated with increased incidence of postpartum depression include family history of depression, stressful life events during early puberty or pregnancy, anxiety or depression during pregnancy, and low social support.

Violence against women is a chronic stressor, so depression may occur when someone is no longer able to respond to the violence.

Criteria

Postpartum depression in the DSM-5 is known as "depressive disorder with peripartum onset". Peripartum onset is defined as starting anytime during pregnancy or within the four weeks following delivery. There is no longer a distinction made between depressive episodes that occur during pregnancy or those that occur after delivery.

Nevertheless, the majority of experts continue to diagnose postpartum depression as depression with onset anytime within the first year after delivery. The criteria required for the diagnosis of postpartum depression are the same as those required to make a diagnosis of non-childbirth-related major depression or minor depression.

The criteria include at least five of the following nine symptoms, within two weeks: Feelings of sadness, emptiness, or hopelessness, nearly every day, for most of the day, or the observation of a depressed mood made by others Loss of interest or pleasure in activities Weight loss or decreased appetite Changes in sleep patterns Feelings of restlessness Loss of energy Feelings of worthlessness or guilt Loss of concentration or increased indecisiveness Recurrent thoughts of death, with or without plans of suicide

Postpartum blues

Postpartum blues, commonly known as "baby blues", is a transient postpartum mood disorder characterized by milder depressive symptoms than postpartum depression. This type of depression can occur in up to 80% of all mothers following delivery. Symptoms typically resolve within two weeks.

Symptoms lasting longer than two weeks are a sign of a more serious type of depression. Women who experience "baby blues" may have a higher risk of experiencing a more serious episode of depression later on.

Postpartum psychosis

Postpartum psychosis (PPP) is a severe episode of manic or depressive psychosis after childbirth. It occurs after 0.1% to 0.2% of pregnancies in women without a history of mental illness. Considered a psychiatric emergency, the disorder is associated with high risks or suicide or infanticide.

Women with PPP typically present with mania, a mixed affective state, or psychotic depression. A subset also experience delusions, hallucinations, thought disorder, severe confusion, or catatonia. Cognitive impairment, irritability, and aggression are also common symptoms.

Symptoms can wax and wane within hours, confusing clinicians and family members. Onset is typically sudden and within the first two weeks after delivery.

About half of women who experience postpartum psychosis have no risk factors, but a prior history of mental illness (especially bipolar disorder), a history of prior episodes of postpartum psychosis, or a family history put some at a higher risk. Postpartum psychosis often requires hospitalization, where treatment is antipsychotic medications, mood stabilizers, and electroconvulsive therapy.

Research suggests PPP falls within the bipolar spectrum, and women who experience a PPP episode have a 50% risk for developing bipolar disorder. Childbirth-related/postpartum post-traumatic stress disorder Parents may suffer from post-traumatic stress disorder (PTSD), or suffer post-traumatic stress disorder symptoms, following childbirth.

While there has been debate in the medical community as to whether childbirth should be considered a traumatic event, the current consensus is childbirth can be a traumatic event. The DSM-IV and DSM-5 (standard classifications of mental disorders used by medical professionals) do not explicitly recognize childbirth-related PTSD, but both allow childbirth to be considered as a potential cause of PTSD.

Childbirth-related PTSD is closely related to postpartum depression. Research indicates mothers who have childbirth-related PTSD also commonly have postpartum depression. Childbirth-related PTSD and postpartum depression have some common symptoms.

Although both diagnoses overlap in their signs and symptoms, some symptoms specific to postpartum PTSD include being easily startled, recurring nightmares and flashbacks, avoiding the baby or anything that reminds one of birth, aggression, irritability, and panic attacks. Real or perceived trauma before, during, or after childbirth is a crucial element in diagnosing childbirth-related PTSD.

Currently, there are no widely recognized assessments that measure postpartum post-traumatic stress disorder in medical settings. Existing PTSD assessments (such as the DSM-IV) have been used to measure childbirth-related PTSD. Some surveys exist to measure childbirth-related PTSD specifically, however, these are not widely used outside of research settings.

Approximately 3–6% of mothers in the postpartum period have childbirth-related PTSD. The percentage of individuals with childbirth-related PTSD is approximately 15–18% in high-risk samples (women who experience severe birth complications, have a history of sexual/physical violence, or have other risk factors).

Research has identified several factors that increase the chance of developing childbirth-related PTSD. These include a negative subjective experience of childbirth, maternal mental health (prenatal depression, perinatal anxiety, acute postpartum depression, and history of psychological problems), history of trauma, complications with delivery and baby (for example emergency cesarean section or NICU admittance), and a low level of social support.

Childbirth-related PTSD has several negative health effects. Research suggests that childbirth-related PTSD may negatively affect the emotional attachment between mother and child. However, maternal depression or other factors may also explain this negative effect.

Childbirth-related PTSD in the postpartum period may also lead to issues with the child's social-emotional development. Current research suggests childbirth-related PTSD results in lower breastfeeding rates and may prevent parents from breastfeeding for the desired amount of time.

Screening

Screening for postpartum depression is critical as up to 50% of cases go undiagnosed in the US, emphasizing the significance of comprehensive screening measures. In the US, the American College of Obstetricians and Gynecologists suggests healthcare providers consider depression screening for perinatal women.

Additionally, the American Academy of Pediatrics recommends pediatricians screen mothers for PPD at 1-month, 2-month, and 4-month visits. However, many providers do not consistently provide screening and appropriate follow-up. For example, in Canada, Alberta is the only province with universal PPD screening.

This screening is carried out by Public Health nurses with the baby's immunization schedule. In Sweden, Child Health Services offers a free program for new parents that includes screening mothers for PPD at 2 months postpartum. However, there are concerns about adherence to screening guidelines regarding maternal mental health.

In addition, systemic biases, such as the tendency to interpret symptoms as emotional or situational rather than clinical, may also contribute to the underdiagnosis of PPD. The Edinburgh Postnatal Depression Scale, a standardized self-reported questionnaire, may be used to identify women who have postpartum depression.

If the new mother scores 13 or more, she likely has PPD and further assessment should follow. Healthcare providers may take a blood sample to test if another disorder is contributing to depression during the screening. The Edinburgh Postnatal Depression Scale is used within the first week of the newborn being admitted.

If mothers receive a score less than 12 they are told to be reassessed because of the depression testing protocol. It is also advised that mothers in the NICU get screened every four to six weeks as their infant remains in the neonatal intensive care unit. Mothers who score between twelve and nineteen on the EPDS are offered two types of support.

The mothers are offered LV treatment provided by a nurse in the NICU and they can be referred to the mental health professional services. If a mother receives a three on item number ten of the EPDS they are immediately referred to the social work team as they may be suicidal.

It is critical to acknowledge the diversity of patient populations diagnosed with postpartum depression and how this may impact the reliability of the screening tools used. There are cultural differences in how patients express symptoms of postpartum depression; those in non-western countries exhibit more physical symptoms, whereas those in Western countries have more feelings of sadness.

Depending on one's cultural background, symptoms of postpartum depression may manifest differently, and non-Westerners being screened in Western countries may be misdiagnosed because their screening tools do not account for cultural diversity. Aside from culture, it is also important to consider one's social context, as women with low socioeconomic status may have additional stressors that affect their postpartum depression screening scores.

Prevention

A 2013 Cochrane review found evidence that psychosocial or psychological intervention after childbirth helped reduce the risk of postnatal depression. These interventions included home visits, telephone-based peer support, and interpersonal psychotherapy.

Support is an important aspect of prevention, as depressed mothers commonly state that their feelings of depression were brought on by "lack of support" and "feeling isolated". Across different cultures, traditional rituals for postpartum care may be preventative for PPD but are more effective when the support is welcomed by the mother.

In couples, emotional closeness and global support by the partner protect against both perinatal depression and anxiety. In 2014, Alasoom and Koura found that compared to 42.9 percent of women who did not get spousal support, only 14.7 percent of women who got spousal assistance had PPD.

Further factors such as communication between the couple and relationship satisfaction have a protective effect against anxiety alone. In those who are at risk counseling is recommended. The US Preventative Services Task Force (USPSTF) conducted a review of evidence which supported the use of counseling interventions such as therapy for the prevention of PPD in high-risk groups.

Women who are considered to be high-risk include those with a past or present history of depression, or with certain socioeconomic factors such as low income or young age. Preventative treatment with antidepressants may be considered for those who have had PPD previously. However, as of 2017, the evidence supporting such use is weak.

Community perinatal mental health teams were launched in England in 2016 to improve access to mental healthcare for pregnant women. They aim to prevent and treat episodes of mental illness during pregnancy and after birth.

Researchers found that in areas of the country where teams were available, women who had previous contact with psychiatric services (many of whom had a previous diagnosis of anxiety or depression) were more likely to access mental health support and had a lower risk of relapse requiring hospital admission in the year after giving birth.

Treatments

Source: Treatment for mild to moderate PPD includes psychological interventions or antidepressants. Women with moderate to severe PPD would likely experience a greater benefit with a combination of psychological and medical interventions. Light aerobic exercise is useful for mild and moderate cases.

Medication

A 2010 review found few studies of medications for treating PPD noting small sample sizes and generally weak evidence. Some evidence suggests that mothers with PPD will respond similarly to people with major depressive disorder. There is low-certainty evidence which suggests that selective serotonin reuptake inhibitors (SSRIs) are an effective treatment for PPD.

The first-line anti-depressant medication of choice is sertraline, an SSRI, as very little of it passes into the breast milk and, as a result, to the child. However, a recent study has found that adding sertraline to psychotherapy does not appear to confer any additional benefit.

Therefore, it is not completely clear which antidepressants, if any, are most effective for the treatment of PPD, and for whom antidepressants would be a better option than non-pharmacotherapy. Some studies show that hormone therapy may be effective in women with PPD, supported by the idea that the drop in estrogen and progesterone levels post-delivery contributes to depressive symptoms.

However, there is some controversy with this form of treatment because estrogen should not be given to people who are at higher risk of blood clots, which include women up to 12 weeks after delivery. Additionally, none of the existing studies included women who were breastfeeding. However, there is some evidence that the use of estradiol patches might help with PPD symptoms.

Oxytocin is an effective anxiolytic and in some cases antidepressant treatment in men and women. Exogenous oxytocin has only been explored as a PPD treatment with rodents, but results are encouraging for potential application in humans. In 2019, the FDA approved brexanolone, a synthetic analog of the neurosteroid allopregnanolone, for use intravenously in postpartum depression.

Allopregnanolone levels drop after giving birth, which may lead to women becoming depressed and anxious. Some trials have demonstrated an effect on PPD within 48 hours from the start of infusion. Other new allopregnanolone analogs under evaluation for use in the treatment of PPD include zuranolone and ganaxolone.

Brexanolone has risks that can occur during administration, including excessive sedation and sudden loss of consciousness, and therefore has been approved under the Risk Evaluation and Mitigation Strategy (REMS) program. The mother is to be enrolled before receiving the medication.

It is only available to those at certified healthcare facilities with a healthcare provider who can continually monitor the patient. The infusion itself is a 60-hour, or 2.5-day, process. People's oxygen levels are to be monitored with a pulse oximeter.

Side effects of the medication include dry mouth, sleepiness, somnolence, flushing, and loss of consciousness. It is also important to monitor for early signs of suicidal thoughts or behaviors. In 2023, the FDA approved zuranolone, sold under the brand name Zurzuvae for treatment of postpartum depression.

Like brexanolone, zuranolone is a synthetic form of allopregnanolone. Zuranolone is administered through a pill, which is more convenient than brexanolone, which is administered through an intravenous injection. Potential side effects of zuranolone include sedation, somnolence, and dizziness, all of which appeared to be well tolerated in a randomized, double blind placebo study.

However, the long term efficacy of zuranolone remains uncertain.

Other

Electroconvulsive therapy (ECT) has shown efficacy in women with severe PPD who have either failed multiple trials of medication-based treatment or cannot tolerate the available antidepressants. Tentative evidence supports the use of repetitive transcranial magnetic stimulation (rTMS).

As of 2013, it is unclear if acupuncture, massage, bright lights, or taking omega-3 fatty acids are useful. National Alliance on Mental Illness: 800-950-NAMI (6264) National Suicide Prevention Lifeline: 800-273-TALK (8255) Postpartum Support International: 800-944-4PPD (4773) SAMHSA's National Hotline: 1-800-662-HELP (4357)

Text derived from https://en.wikipedia.org/w/index.php?oldid=1374626049 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

23 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.